Разрывы в ответственности по контрактам тормозят клинические испытания и стоят миллионы

Accountability Gaps Can Break Clinical Supply Contracts By Eshaan Jain, Senior Consultant, Mphasis I have worked on both sides of this problem. At Amazon, I co-built a machine learning system that extracted clause-level data from PDF contracts across a $40 billion annual supply chain portfolio. Today, as lead product owner for Salesforce/Vlocity contract lifecycle management (CLM) at T-Mobile, engaged through Mphasis, I run the process that turns a negotiated agreement into a document my team can actually query, and we cut contract creation time in half. Clinical trial execution runs on a stack of contracts that rarely gets read as a stack: a clinical trial agreement (CTA) with each site, a master service agreement with the CRO, a distribution agreement with the depot, and a service level agreement with the courier moving product between them. A National Institutes of Health-funded study of contract processing across 29 Clinical and Translational Science Award (CTSA) sites found trial agreement negotiation routinely exceeding 100 days.1 Applied Clinical Trials has reported that contracting bottlenecks are tied to nearly half of all study start-up delays, at a cost sponsors have put between $600,000 and $8 million per day of delay.2 Most of the attention on that problem goes to speeding up any one of those agreements. The bigger gap is between them. The Gap Sits Between The Contracts Picture a shipment moving from a central depot to a trial site. The courier's SLA with the depot defines a 4-hour tolerance for a temperature excursion before the shipment is flagged. The depot's distribution agreement with the sponsor defines a 2-hour tolerance before the batch must be quarantined pending review. Nobody wrote these two numbers down next to each other because they live in two different contracts, negotiated by two different teams, at two different times. When a shipment sits outside its labeled range for 3 hours, the courier's paperwork says nothing happened. The depot's paperwork says a quarantine review is overdue. The site, waiting on the shipment, has no contract at all that tells it which number applies. That happens when contracts are negotiated as isolated documents rather than as one operational picture, not because anyone drafted a clause incorrectly. Accountability Gaps Are Locked In Each PDF A CTA typically defines the site's responsibilities for drug accountability, temperature logging, and reporting protocol deviations. A CRO master service agreement defines who is responsible for data quality oversight across those same sites. A depot agreement defines reorder thresholds and excursion tolerances. A courier SLA defines transit time and in-transit monitoring requirements. Each of those documents assigns responsibility for a part of the same physical shipment, and none of them cross-references the others. At Amazon, the same category of terms appeared in last-mile carrier and vendor agreements: service levels, pricing tiers, penalty clauses, and renewal windows, each negotiated separately from the contracts governing the leg before and the leg after. Nobody could see the whole shipment's obligations without opening four separate documents and reconciling them by hand. Drug accountability is a good example of how far this can drift. The CTA usually makes the site responsible for logging every dose administered and reconciling it against what the depot shipped. The CRO MSA usually makes the CRO responsible for verifying that reconciliation happened. The depot agreement rarely mentions either obligation at all, because from the depot's side, its job ends at delivery. During a routine audit, three different parties can each point to a different document and correctly say the drug accountability gap is not theirs to close, because each contract was written as if the other two did not exist. What CLM Discipline Changes Running CLM for CPQ at various clients taught me where the real time goes in a contract cycle. It is rarely the negotiation itself. It is the handoffs and the fact that nobody owns the view across documents that were negotiated independently. Cutting contract creation time in half came from standardizing the clause library so negotiators could reuse approved language instead of drafting from scratch and from capturing structured metadata (party, term, pricing, key obligations, renewal date) at the point of execution rather than after the fact. The clinical trial equivalent is a shared clause taxonomy that spans the CTA, the CRO MSA, the depot agreement, and the courier SLA: temperature excursion tolerance, drug accountability ownership, data quality oversight, and reorder thresholds. Tag every one of those four document types against the same taxonomy at signature, and a mismatch like the one above becomes visible before a shipment is in transit, not after a quarantine review is already overdue. Where This Connects To Controls And Forecasting A contract that assigns responsibility clearly is a control. A contract that assigns responsibility inconsistently across four documents governing the same shipment is a gap that no validation package or audit trail will ever catch, because the systems are working exactly as each individual contract specifies. A reorder threshold or excursion tolerance buried in a contract is also a forecasting input. None of these should require someone to compare four PDFs by hand when a shipment, a quality review, or an audit needs the answer, and none of them should surface for the first time during an incident review instead of during contract negotiation. The Action You Need To Take Before Signing Before your next CTA, CRO MSA, depot agreement, or courier SLA gets signed, check it against the other three documents governing the same shipment chain, not just against your own template. If the temperature excursion tolerance, the accountability owner, or the reorder threshold differ across any two of them, you have a gap that will surface during an actual excursion, not during the negotiation. Reconcile it on paper now, with a named owner for each obligation, or reconcile it during an incident later, when a shipment is sitting outside its labeled range, and three different vendors are pointing at each other's contracts to explain why it is still there. References: - National Institutes of Health-funded observational study of contract processing at 29 Clinical and Translational Science Award (CTSA) sites, published in PMC (PubMed Central): pmc.ncbi.nlm.nih.gov/articles/PMC3740442. Secondary source: ContractSafe, "Clinical Trials Stall Because of Contracts. Here's How to Fix It.": www.contractsafe.com/blog/pharmaceutical-contract-managment - Applied Clinical Trials, cited by ContractSafe, on contracting bottlenecks, study start-up delays, and per-day delay cost estimates: www.contractsafe.com/blog/pharmaceutical-contract-managment About The Author: Eshaan Jain is a senior consultant at Mphasis and serves as the lead product owner for Salesforce/Vlocity CPQ and CLM at T-Mobile, engaged through Mphasis’s consulting services. He previously worked on IT general controls (ITGCs), business process controls, and application security assessments at PwC and Accenture. He is an IEEE senior member and holds professional membership with Forbes Tech Council, ACM, IEEE, Isaca, and AAAI.